Compare PubMatic Inc (PUBM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PubMatic Inc vs Recursion Pharmaceuticals Inc — how do they compare? PubMatic Inc trades at $18.56 (market cap $850.88M), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.5× PubMatic Inc's market cap, and PubMatic Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold PubMatic Inc for 40 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| PUBM | RXRX | |
|---|---|---|
Market Cap | $850.88M | $2.14B |
Volume | 997,698 | 30,789,535 |
Sector | Technology | Health |
52-Week High | $19.18 | $6.79 |
52-Week Low | $6.28 | $2.84 |
Typical Hold Time | 40 Days | 22 Days |
Enterprise Value | $754.01M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PubMatic trades at $18.57, up 1.2% with a bullish technical signal. The stock shows strong analyst support with 11 buy ratings and a $19.89 consensus target. Recent Q2 2026 earnings beat expectations with $0.12 EPS versus $0.03 estimate, while revenue grew 10.5% year-over-year. The company maintains robust operating cash flow of $81M in 2025 and has strengthened its leadership with new executive appointments.
Despite negative net margins, PubMatic demonstrates operational strength through consistent cash generation and revenue growth. The primary investment opportunity lies in AI-driven ad tech expansion and market share gains, while risks include competitive pressures and profitability challenges. The stock appears fairly valued with potential upside to analyst targets.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PubMatic Inc
PubMatic Inc is engaged in the digital advertising business. The company provides a specialized cloud infrastructure platform that enables real-time programmatic advertising transactions. The platform helps independent app developers and publishers to control and maximize their digital advertising businesses.
Read more on PUBM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
